{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "2543283",
  "DateCompleted": {
    "Year": "1989",
    "Month": "07",
    "Day": "07"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "05",
    "Day": "26"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0066-4804",
      "JournalIssue": {
        "Volume": "33",
        "Issue": "4",
        "PubDate": {
          "Year": "1989",
          "Month": "Apr"
        }
      },
      "Title": "Antimicrobial agents and chemotherapy",
      "ISOAbbreviation": "Antimicrob Agents Chemother"
    },
    "ArticleTitle": "Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R61837).",
    "Pagination": {
      "StartPage": "522",
      "EndPage": "525",
      "MedlinePgn": "522-5"
    },
    "Abstract": {
      "AbstractText": [
        "This report describes double-blind placebo-controlled trials of a new synthetic antirhinovirus drug, R61837, which showed it to be effective in suppressing colds in human volunteers challenged with rhinovirus type 9. In one trial, R61837 was given by intranasal spray six times a day, commencing 28 h before virus challenge; treatment continued for 4 days and one dose (total dose, 25 mg). This regimen suppressed symptoms until 48 h after medication ceased, at which time colds developed. In another trial, medication with R61837 commenced at 4 h before virus challenge and continued for a total of 6 days (total dose, 36 mg). The drug produced substantial reductions in both the mean daily clinical score and the mean daily nasal secretion weight compared with patients given the placebo. These differences reached statistical significance for 2 and 4 days, respectively. In a further trial, intranasal R61837 was not effective in treating colds even when given shortly after the onset of symptoms and in doses of up to 15 mg/day."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Common Cold Unit, Medical Research Council, Salisbury, United Kingdom."
          }
        ],
        "LastName": "al-Nakib",
        "ForeName": "W",
        "Initials": "W"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Higgins",
        "ForeName": "P G",
        "Initials": "PG"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Barrow",
        "ForeName": "G I",
        "Initials": "GI"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Tyrrell",
        "ForeName": "D A",
        "Initials": "DA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Andries",
        "ForeName": "K",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Vanden Bussche",
        "ForeName": "G",
        "Initials": "G"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Taylor",
        "ForeName": "N",
        "Initials": "N"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Janssen",
        "ForeName": "P A",
        "Initials": "PA"
      }
    ],
    "PublicationTypeList": [
      "Clinical Trial",
      "Controlled Clinical Trial",
      "Journal Article",
      "Randomized Controlled Trial"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Antimicrob Agents Chemother",
    "NlmUniqueID": "0315061",
    "ISSNLinking": "0066-4804"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Pyridazines"
    },
    {
      "RegistryNumber": "100241-46-1",
      "NameOfSubstance": "R 61837"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Administration, Intranasal"
    },
    {
      "QualifierName": [
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Clinical Trials as Topic"
    },
    {
      "QualifierName": [
        "microbiology",
        "prevention & control"
      ],
      "DescriptorName": "Common Cold"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Double-Blind Method"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Pyridazines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Random Allocation"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Rhinovirus"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Time Factors"
    }
  ]
}